Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q3 FY2024 Earnings Presentation
20 slides from Glenmark Pharmaceuticals's earnings presentation, Feb 14, 2024
Slide 1: Stock exchange filing cover letter
February 14, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 532296
Slide 2: Investor Presentation: Q3 FY24
Investor Presentation: Q3 FY24 14 February 2024
Slide 3: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 4: Strategic Restructuring For Sharper Focus On The Three Businesses
Strategic Restructuring For Sharper Focus On The Three Businesses Alliance between GPL and its 100% subsidiary, Ichnos Sciences Inc. Separate Board of Directors Innovation biotech focused on development of novel molecules as Focused on building a global potential treatment options for oncology formu
Slide 5: Committed to Sustainability across all our operations globally
Committed to Sustainability across all our operations globally Environmental Social Governance Become carbon neutral by 2030* 16 global safety programs by 2023 Maintain an ethical business culture to Achieve water neutral operations by Aspire to impact 3 million lives by 2025 drive robust governance
Slide 6: Q3 & 9M FY24 Summary – Consolidated (GPL + GLS)
Q3 & 9M FY24 Summary – Consolidated (GPL + GLS) Q3 FY24 9M FY24 Revenue from operations at Rs. 29,096 Mn with decline of 16% Revenue from operations at Rs. 98,991 Mn with growth of YoY due to one-time impact on India business 2.9% Excluding the impact, approx. revenue growth estimated to be
Slide 7: Q3 & 9M FY24 Summary - Reported (Continuing Operations)
Q3 & 9M FY24 Summary - Reported (Continuing Operations – Glenmark Group excluding GLS) Q3 FY24 9M FY24 Revenue from operations at Rs. 25,067 Mn with decline of 19% Revenue from operations at Rs. 87,501 Mn with growth of 2% YoY due to one-time impact on India business Excluding the one-time imp
Slide 8: Consolidated Revenues from Operations – Q3 FY24
Consolidated Revenues from Operations – Q3 FY24 Third Quarter ended Second Quarter ended December 31 September 30 YoY Growth QoQ Growth Rs Mn FY 2023-24 FY 2022-23 FY 2022-23 (%) (%) India 2,622 10,745 -75.6% 11,217 -76.6% North America 7,629 8,373 -8.9% 7,392 3.2% Europe 6,357 4,932 28.9% 5,997 6.0
Slide 9: Consolidated Revenues from Operations – 9M FY24
Consolidated Revenues from Operations – 9M FY24 Nine Months ended December 31 YoY Growth Rs Mn FY 2023-24 FY 2022-23 (%) India 24,482 32,014 -23.5% North America 23,105 22,534 2.5% Europe 18,086 12,016 50.5% Rest of the World1 20,086 16,921 18.7% API 11,828 10,751 10.0% Total 97,587 94,236 3.6% Othe
Slide 10: Q3 & 9M FY24 P&L Highlights – Consolidated (GPL + GLS)
Q3 & 9M FY24 P&L Highlights – Consolidated (GPL + GLS) Rs. Mn Q3 FY24 Q3 FY23 9M FY24 9M FY23 Revenues from Operations 29,096 34,639 98,991 96,164 EBITDA (353) 6,202 12,262 16,734 EBITDA margin (%) -1.2% 17.9% 12.4% 17.4% Other Income (exp) 463 764 733 3,570 Exceptional gain (loss) (767) 339 (4,542)
Slide 11: Q3 & 9M FY24 P&L Highlights – Reported (Continuing Operations)
Q3 & 9M FY24 P&L Highlights – Reported (Continuing Operations – Glenmark Group excluding GLS) Rs. Mn Q3 FY24 Q3 FY23 9M FY24 9M FY23 Revenues from Operations 25,067 31,002 87,501 85,827 EBITDA (2,086) 4,740 6,910 12,371 EBITDA margin (%) -8.3% 15.3% 7.9% 14.4% Other Income (exp) 454 706 668 3,313 Ex
Slide 12: India
25% 9M FY24 India YoY: -75.6% Revenue (INR Mn) QoQ: -76.6% Continued outperformance in Launched Lirafit™ - first 11,217 secondary sales in Q3 and MAT biosimilar of liraglutide in India, 10,745 December 2023 at 70% lower cost of therapy Key Highlights One-time impact on India business revenue as th
Slide 13: North America
25% 9M FY24 North America YoY: -8.9% Revenue (INR Mn) QoQ: 3.2% Significant expansion of 7 launches in Q3 FY24 injectable portfolio – 5 products 8,373 commercialized in the market 7,629 7,392 Key Highlights Q3 Sales impacted due to continued price erosion in the base business and lack of significa
Slide 14: Europe
25% 9M FY24 Europe YoY: 28.9% Revenue (INR Mn) QoQ: 6.0% RYALTRIS® continues to sustain Strong growth of branded 6,357 share in all key markets business in the CEE markets 5,997 4,932 Key Highlights Western European (WEU) business clocked ~20% growth for Q3 mainly led by the United Kingdom (UK), S
Slide 15: Rest of the World (ROW)
25% 9M FY24 Rest of the World (ROW)1 YoY: 10.8% Revenue (INR Mn) QoQ: -1.0% Growth in the base business Respiratory launches – key driver 7,250 7,324 across all sub-regions of ROW of growth in the region 6,541 Key Highlights Russia: Glenmark ranked 9th in Dermatology and 2nd in Expectorants market
Slide 16: Creating Global Brands - RYALTRIS
Creating Global Brands - RYALTRIS® Value market shares of RYALTRIS® across key geographies (Top 10 products within “R1A1 – Nasal Corticosteroids without Anti Marketing applications submitted in more than 70 countries across the world. Infectives” category as per IQVIA + RYALTRIS®): The product has
Slide 17: ICHNOS GLENMARK INNOVATION
ICHNOS GLENMARK INNOVATION The Company and its global fully integrated, clinical‐stage biotech subsidiary, Ichnos Sciences Inc. (Ichnos), recently announced the launch of their alliance – Ichnos Glenmark Innovation – to accelerate new drug discovery in cancer treatment. This alliance combines Gl
Slide 18: ICHNOS GLENMARK INNOVATION
ICHNOS GLENMARK INNOVATION GRC 54276 is being developed as an orally administered IO-adjuvant treatment for patients with solid tumors. GRC 54276 is a novel, orally active HPK1 inhibitor that demonstrates stand- alone efficacy and enhances current immunotherapy efficacy. GRC 54276 is currently bei
Slide 19: IGI Biologics Pipeline
ICHNOS GLENMARK INNOVATION IGI Biologics Pipeline - First Wave Focuses on T-Cell Engagers and Macrophage Modulators for Oncology Molecule Phase/Status Lead Indication Mechanism/Class IGI Biologic Assets in Autoimmune (AI) Disease ISB 1442 Relapsed / Refractory Multiple CD38 x CD47 BEAT® Molecule Pot
Slide 20: Glenmark
G Glenmark
Glenmark Pharmaceuticals — Q3 FY2024 Earnings Presentation on 6ix